Table 4. Side effects of 28 patents with ICC in the treatment of CyberKnife SBRT [n(%)].
| CTC 4.0 toxicity* | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| Fatigue | 4 (14.3%) | 3 (10.7%) | 0 (0) | 0 (0) | 0 (0) |
| Lethargy | 5 (17.9%) | 2 (7.1%) | 0 (0) | 0 (0) | 0 (0) |
| Pleural effusion | 2 (7.1%) | 1 (3.6%) | 0 (0) | 0 (0) | 0 (0) |
| Gastrointestinal | |||||
| Nausea | 8 (28.6%) | 3 (10.7%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Anorexia | 10 (35.7%) | 2 (7.1%) | 2 (7.1%) | 0 (0) | 0 (0) |
| Vomiting | 5 (17.9%) | 2 (7.1%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Duodenal ulcer | 2 (7.1%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Gastric ulcer | 2 (7.1%) | 1 (3.6%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Hepatic | |||||
| ALT | 3 (10.7%) | 4 (14.3%) | 2 (7.1%) | 0 (0) | 0 (0) |
| AST | 5 (17.9%) | 6 (21.4%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Albumin | 1 (3.6%) | 6 (21.4%) | 1 (3.6%) | 0 (0) | 0 (0) |
| ALP | 2 (7.1%) | 3 (10.7%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Bilirubin | 2 (7.1%) | 4 (14.3%) | 2 (7.1%) | 0 (0) | 0 (0) |
| Bone marrow | |||||
| WBC | 7 (25%) | 3 (10.7%) | 1 (3.6%) | 0 (0) | 0 (0) |
| Hb | 3 (10.7%) | 2 (7.1%) | 1 (3.6%) | 0 (0) | 0 (0) |
| PLT | 10 (35.7%) | 2 (7.1%) | 1 (3.6%) | 0 (0) | 0 (0) |
*CTC 4.0: The Common Toxicity Criteria Adverse Events (version 4.0).